Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Clearside Biomedical, Inc. (CLSD : NSDQ)

• Company Description    Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding diseases of the eye using Clearside proprietary suprachoroidal space(TM) microinjector. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related macular degeneration. Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia. Number of Employees: 32

• Price / Volume Information    Yesterday's Closing Price: $3.90 Daily Weekly Monthly 20 Day Moving Average: 30,404 shares Shares Outstanding: 5.24 (millions) Market Capitalization: $20.42 (millions) Beta: 2.05 52 Week High: $17.40 52 Week Low: $3.33 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -1.76% -4.65% 12 Week -39.04% -44.27% Year To Date -72.62% -76.63%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 900 NORTH POINT PARKWAY SUITE 200 - ALPHARETTA,GA 30005 USA ph: 678-270-3631 fax: 678-270-4033 ir@clearsidebio.com http://www.clearsidebio.com

• General Corporate Information    Officers George Lasezkay - President; Chief Executive Officer and Director Charles A. Deignan - Chief Financial Officer Anthony S. Gibney - Director Richard Croarkin - Director Jeffrey L. Edwards - Director Peer Information Clearside Biomedical, Inc. (CORR.) Clearside Biomedical, Inc. (RSPI) Clearside Biomedical, Inc. (CGXP) Clearside Biomedical, Inc. (BGEN) Clearside Biomedical, Inc. (GTBP) Clearside Biomedical, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 185063203 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: 5.24 Most Recent Split Date: 9.00 (0.07:1) Beta: 2.05 Market Capitalization: $20.42 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.67 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.80 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 4.90 EPS Growth vs. Year Ago Period: 40.00% vs. Previous Quarter: 45.45% Sales Growth vs. Year Ago Period: 446.67% vs. Previous Quarter: -78.88% ROE 09/30/25 - - 06/30/25 - - 03/31/25 - - ROA 09/30/25 - - 06/30/25 - -124.15 03/31/25 - -114.23 Current Ratio 09/30/25 - - 06/30/25 - 3.87 03/31/25 - 3.19 Quick Ratio 09/30/25 - - 06/30/25 - 3.87 03/31/25 - 3.19 Operating Margin 09/30/25 - - 06/30/25 - -665.19 03/31/25 - -818.57 Net Margin 09/30/25 - - 06/30/25 - -665.19 03/31/25 - -818.57 Pre-Tax Margin 09/30/25 - - 06/30/25 - -648.06 03/31/25 - -799.60 Book Value 09/30/25 - - 06/30/25 - -9.31 03/31/25 - -8.91 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Capital 09/30/25 - - 06/30/25 - - 03/31/25 - -

Powered by Zacks Investment Research ©